2021
517. Subcutaneous Sarilumab for the Treatment of Hospitalized patients with Moderate to Severe COVID19 Disease: A Pragmatic, Embedded, Multi-Center Randomized Clinical Trial
Branch-Elliman W, Ferguson R, Doros G, Woods P, Leatherman S, Strymish J, Datta R, Goswami R, Jankowich M, Shah N, Taylor T, Page S, Schiller S, Shannon C, Hau C, Flynn M, Holmberg E, Visnaw K, Dhond R, Brophy M, Monach P. 517. Subcutaneous Sarilumab for the Treatment of Hospitalized patients with Moderate to Severe COVID19 Disease: A Pragmatic, Embedded, Multi-Center Randomized Clinical Trial. Open Forum Infectious Diseases 2021, 8: 360-360. PMCID: PMC8690689, DOI: 10.1093/ofid/ofab466.716.Peer-Reviewed Original ResearchSubcutaneous sarilumabStandard careMechanical ventilationLearning healthcare systemClinical trialsSevere COVID-19 diseaseCOVID-19Rate of intubationSevere COVID-19Trial of patientsCare clinical trialsIL-6 inhibitionTreatment of patientsNumber of patientsStandard of careHealthcare systemEvidence of benefitCOVID-19 diseaseData monitoring committeeA PragmaticPrimary endpointChart reviewHospitalized patientsPrimary outcomeSupplemental oxygen
2018
Increased Fluoroquinolone-Susceptibility and Preserved Nitrofurantoin-Susceptibility among Escherichia coli Urine Isolates from Women Long-Term Care Residents: A Brief Report
Datta R, Advani S, Rink A, Bianco L, Van Ness PH, Quagliarello V, Juthani-Mehta M. Increased Fluoroquinolone-Susceptibility and Preserved Nitrofurantoin-Susceptibility among Escherichia coli Urine Isolates from Women Long-Term Care Residents: A Brief Report. Open Access Journal Of Gerontology & Geriatric Medicine 2018, 4: 555636. PMID: 30465048, PMCID: PMC6241532, DOI: 10.19080/oajggm.2018.04.555636.Peer-Reviewed Original ResearchLong-term care residentsUrinary tract infectionUrine isolatesCare residentsTract infectionsUncomplicated urinary tract infectionsLong-term care facilitiesTrimethoprim/sulfamethoxazoleEmpiric therapyCommon indicationOptimal therapyUrine cultureUrinary isolatesAntimicrobial therapyClinical trialsNitrofurantoin susceptibilityCare facilitiesFluoroquinolone susceptibilityAntimicrobial susceptibilityPredominant organismTherapyInfectionCefazolinIsolatesBacterial isolates
2017
Serious adverse events of older adults in nursing home and community intervention trials
Datta R, Trentalange M, Van Ness PH, McGloin JM, Guralnik JM, Miller ME, Walkup MP, Nadkarni N, Pahor M, Gill TM, Quagliarello V, Juthani-Mehta M, Group F. Serious adverse events of older adults in nursing home and community intervention trials. Contemporary Clinical Trials Communications 2017, 9: 77-80. PMID: 29696228, PMCID: PMC5898490, DOI: 10.1016/j.conctc.2017.12.004.Peer-Reviewed Original ResearchUnanticipated serious adverse eventsSerious adverse eventsNursing home residentsTotal serious adverse eventsHome residentsSAE incidenceAdverse eventsClinical trialsOlder adultsCommunity dwellersNursing homesIncidence of SAEsFemale nursing home residentsProportion of patientsRandomized clinical trialsCommunity intervention trialStructured physical activityCranberry capsulesLifestyle interventionRandomized trialsIntervention trialsElders StudyHealth centersSecondary data analysisPhysical activity